정부/공공기관
임상시험센터
CRO
분석CRO/센트럴랩
유관기관/협회
정보서비스
해외 유관 기관
* CRO 게재 기준: CRO자율등록 기관
ClinicalTrials.gov에 등록된 정보를 기준으로 코로나-19(COVID-19) 관련 글로벌 임상시험 현황을 제공합니다.
전체 2550건이 검색되었습니다.
No. | Status | Study Title | Conditions | Interventions | Phase | Sponsor/Collaborators | Funder Type | Number Enrolled | Sex | Age | Locations |
---|---|---|---|---|---|---|---|---|---|---|---|
191 | Recruiting | Therapeutic Use of Convalescent Plasma in the Treatment of Patients With Moderate to Severe COVID-19 | Severe Acute Respiratory Syndrome Coronavirus 2 | Biological: COVID-19 convalescent plasma (CCP) plus standard of care (SOC) Biological: Standard of care (SOC) plus placebo |
Phase 3 | South African National Blood Service | OTHER | 600 | All | 18 Years | Universitas Hospital, Bloemfontein, Free State, South Africa Mitchells Plain Hospital, Cape Town, Western Cape, South Africa |
190 | Not yet recruiting | Therapeutic Vaccine Trial of COVID-19 for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection | COVID | Biological: Covax-19™ | Phase 1 | GeneCure Biotechnologies | INDUSTRY | 32 | All | 18 Years ~ 60 Years | |
189 | Withdrawn | Therapy for Pneumonia Patients iInfected by 2019 Novel Coronavirus | COVID-19 | Biological: UC-MSCs Other: Placebo |
Not Applicable | Puren Hospital Affiliated to Wuhan University of Science and Technology, Wuhan Hamilton Bio-technology Co., Ltd | OTHER | 0 | All | 18 Years ~ 75 Years | Puren Hospital Affiliated to Wuhan University of Science and Technology, Wuhan, Hubei, China |
188 | Not yet recruiting | Third Dose of COVID-19 Vaccine in LTCF Residents | Coronavirus Infection | Drug: MRNA-1273 Drug: Prevnar13 |
Phase 4 | Mark Loeb | OTHER | 414 | All | 65 Years | McMaster University, Hamilton, Ontario, Canada |
187 | Active, not recruiting | Third Dose of Moderna COVID-19 Vaccine in Transplant Recipients | Covid19 | Biological: mRNA-1273 vaccine Other: Normal Saline Placebo |
Phase 4 | University Health Network, Toronto | OTHER | 120 | All | 18 Years | University Health Network, Toronto General Hospital, Toronto, Ontario, Canada University Health Network, Toronto General Hospital, Multi-Organ Transplant, Toronto, Ontario, Canada |
186 | Recruiting | Third Dose of mRNA Vaccination to Boost COVID-19 Immunity | COVID 19 Vaccine | Biological: BNT162b2 | Phase 4 | The University of Hong Kong | OTHER | 100 | All | 30 Years | The University of Hong Kong, Hong Kong, Hong Kong |
185 | Not yet recruiting | Third Dose Vaccination With AstraZeneca or Pfizer COVID-19 Vaccine Among Adults Received Sinovac COVID-19 Vaccine | COVID-19 VACCINE | Biological: AstraZeneca ChAdOx1 AZD1222 vaccine (AZ) full dose Biological: Pfizer/BioNTech BNT162b2 vaccine (PF) full dose Biological: AstraZeneca ChAdOx1 AZD1222 vaccine (AZ) half dose Biological: Pfizer/BioNTech BNT162b2 vaccine (PF) half dose |
Phase 2 | Mahidol University, Clinixir Co., Ltd., Program Management Unit-C (PMU-C), governed by Ministry of Higher Education, Science, Research and Innovation (MHESI) | OTHER | 1320 | All | 18 Years ~ 59 Years |